Oncimmune Holdings plc, a precision medicine company, provides autoantibody biomarker profiling in immuno-oncology, autoimmune, and infectious diseases in Europe and internationally. The company offers ImmunoINSIGHTS platform, an autoantibody profiling service that provides insights to discover and validate novel biomarkers, validate drug mode of action, improve treatment responses and adverse event (irAE) prediction, patient screening, and diagnostic accuracy; Sero Tag, a discovery engine for the identification of relevant biomarker pool for target discovery or companion diagnostics; NavigAID for creation of a disease-specific biomarker panel; and Autoantibody Biomarkers, a companion diagnostic biomarker. It also provides business development and marketing services. Oncimmune Holdings plc was incorporated in 2015 and is headquartered in Leeds, the United Kingdom.
Metrics to compare | ONCON | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCONPeersSector | |
---|---|---|---|---|
P/E Ratio | 0.0x | −2.7x | −0.5x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price/Book | 0.0x | 1.9x | 2.6x | |
Price / LTM Sales | 0.0x | 9.2x | 3.3x | |
Upside (Analyst Target) | 0.0% | 0.0% | 45.4% | |
Fair Value Upside | Unlock | 15.9% | 7.7% | Unlock |